These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 20367229

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART.
    Marchetti G, Gori A, Casabianca A, Magnani M, Franzetti F, Clerici M, Perno CF, Monforte Ad, Galli M, Meroni L.
    AIDS; 2006 Aug 22; 20(13):1727-36. PubMed ID: 16931937
    [Abstract] [Full Text] [Related]

  • 4. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
    Goicoechea M, Smith DM, Liu L, May S, Tenorio AR, Ignacio CC, Landay A, Haubrich R.
    J Infect Dis; 2006 Jul 01; 194(1):29-37. PubMed ID: 16741879
    [Abstract] [Full Text] [Related]

  • 5. Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome.
    Onen NF, Overton ET, Presti R, Blair C, Powderly WG, Mondy K.
    HIV Med; 2009 Aug 01; 10(7):439-46. PubMed ID: 19459993
    [Abstract] [Full Text] [Related]

  • 6. Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy.
    Siddique MA, Hartman KE, Dragileva E, Dondero M, Gebretsadik T, Shintani A, Peiperl L, Valentine F, Kalams SA.
    J Infect Dis; 2006 Sep 01; 194(5):661-5. PubMed ID: 16897665
    [Abstract] [Full Text] [Related]

  • 7. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
    Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, Knysz B, Antunes F, Reiss P, Lundgren JD.
    AIDS; 2006 May 12; 20(8):1141-50. PubMed ID: 16691065
    [Abstract] [Full Text] [Related]

  • 8. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
    Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, Swiss HIV Cohort Study.
    Clin Infect Dis; 2005 Aug 01; 41(3):361-72. PubMed ID: 16007534
    [Abstract] [Full Text] [Related]

  • 9. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A, Leti W, De Santis W, Marziali M, Esposito A, Fimiani C, Luzi G, Pinti M, Cossarizza A, Aiuti F, Mezzaroma I.
    Clin Infect Dis; 2008 Jun 15; 46(12):1902-10. PubMed ID: 18462177
    [Abstract] [Full Text] [Related]

  • 10. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
    Wolbers M, Battegay M, Hirschel B, Furrer H, Cavassini M, Hasse B, Vernazza PL, Bernasconi E, Kaufmann G, Bucher HC, Swiss HIV Cohort Study.
    Antivir Ther; 2007 Jun 15; 12(6):889-97. PubMed ID: 17926643
    [Abstract] [Full Text] [Related]

  • 11. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M, Swiss HIV Cohort Study Group.
    Arch Intern Med; 2003 Oct 13; 163(18):2187-95. PubMed ID: 14557216
    [Abstract] [Full Text] [Related]

  • 12. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Liu ZY, Guo FP, Han Y, Qiu ZF, Zuo LY, Li YL, Li TS.
    Chin Med J (Engl); 2009 Oct 20; 122(20):2497-502. PubMed ID: 20079166
    [Abstract] [Full Text] [Related]

  • 13. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
    Castagna A, Galli L, Torti C, D'Arminio Monforte A, Mussini C, Antinori A, Cozzi-Lepri A, Ladisa N, De Luca A, Seminari E, Gianotti N, Lazzarin A.
    Antivir Ther; 2010 Oct 20; 15(2):165-75. PubMed ID: 20386071
    [Abstract] [Full Text] [Related]

  • 14. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
    Stone SF, Price P, French MA.
    HIV Med; 2005 Jul 20; 6(4):278-83. PubMed ID: 16011533
    [Abstract] [Full Text] [Related]

  • 15. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD, HepaI.Co.N.A. Study Group, Italian Cohort Naive for Antiretrovirals Study Group.
    Clin Infect Dis; 2005 Jun 15; 40(12):e101-9. PubMed ID: 15909251
    [Abstract] [Full Text] [Related]

  • 16. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation.
    Molina-Pinelo S, Vallejo A, Díaz L, Soriano-Sarabia N, Ferrando-Martínez S, Resino S, Muñoz-Fernández MA, Leal M.
    J Antimicrob Chemother; 2009 Sep 15; 64(3):579-88. PubMed ID: 19608579
    [Abstract] [Full Text] [Related]

  • 17. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C, Lapadula G, Barreiro P, Soriano V, Mandalia S, De Silvestri A, Suter F, Maggiolo F, Antinori A, Antonucci F, Maserati R, El Hamad I, Pierotti P, Sighinolfi L, Migliorino G, Ladisa N, Carosi G, Italian MASTER Cohort.
    J Antimicrob Chemother; 2007 Jun 15; 59(6):1141-7. PubMed ID: 17434879
    [Abstract] [Full Text] [Related]

  • 18. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy.
    Lim A, Tan D, Price P, Kamarulzaman A, Tan HY, James I, French MA.
    AIDS; 2007 Jul 31; 21(12):1525-34. PubMed ID: 17630546
    [Abstract] [Full Text] [Related]

  • 19. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
    Moore RD, Keruly JC.
    Clin Infect Dis; 2007 Feb 01; 44(3):441-6. PubMed ID: 17205456
    [Abstract] [Full Text] [Related]

  • 20. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A, Cox AE, Shamji MH, John L, Nelson M, Henderson DC, Gotch FM, Gazzard BG, Kelleher P.
    Antivir Ther; 2007 Feb 01; 12(6):971-5. PubMed ID: 17926652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.